AIMS/HYPOTHESIS: In contrast to microalbuminuric type 2 diabetic patients, the factors correlated with urinary albumin excretion are less well known in normoalbuminuric patients. This may be important because even within the normoalbuminuric range, higher rates of albuminuria are known to be associated with higher renal and cardiovascular risk. METHODS: At the time of screening for the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study, the urinary albumin/creatinine ratio (UACR) was 0.44 mg/mmol in 4,449 type 2 diabetic patients. The independent correlates of UACR were analysed. RESULTS: Independent correlates of UACR during baseline were (in descending order): night-time systolic BP (r(s) = 0.19); HbA(1c) (r(s) = 0.18); mean 24 h systolic BP (r(s) = 0.16); fasting blood glucose (r(s) = 0.16); night-time diastolic BP (r(s) = 0.12); office systolic BP, sitting (r(s) = 0.11), standing (r(s) = 0.10); estimated GFR (r(s) = 0.10); heart rate, sitting (r(s) = 0.10); haemoglobin (r(s) = -0.10); triacylglycerol (r(s) = 0.09); and uric acid (r(s) = -0.08; all p <or= 0.001). Significantly higher albumin excretion rates were found for the following categorical variables: higher waist circumference (more marked in men); presence of the metabolic syndrome; smoking (difference more marked in males); female sex; antihypertensive treatment; use of amlodipine; insulin treatment; family history of diabetes; and family history of cardiovascular disease (more marked in women). CONCLUSIONS/ INTERPRETATION: Although observational correlations do not prove causality, in normoalbuminuric type 2 diabetic patients the albumin excretion rate is correlated with many factors that are potentially susceptible to intervention. TRIAL REGISTRATION: ClinicalTrials.gov ID no.: NCT00185159 FUNDING: This study was sponsored by Daichii-Sankyo.
RCT Entities:
AIMS/HYPOTHESIS: In contrast to microalbuminuric type 2 diabeticpatients, the factors correlated with urinary albumin excretion are less well known in normoalbuminuric patients. This may be important because even within the normoalbuminuric range, higher rates of albuminuria are known to be associated with higher renal and cardiovascular risk. METHODS: At the time of screening for the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study, the urinary albumin/creatinine ratio (UACR) was 0.44 mg/mmol in 4,449 type 2 diabeticpatients. The independent correlates of UACR were analysed. RESULTS: Independent correlates of UACR during baseline were (in descending order): night-time systolic BP (r(s) = 0.19); HbA(1c) (r(s) = 0.18); mean 24 h systolic BP (r(s) = 0.16); fasting blood glucose (r(s) = 0.16); night-time diastolic BP (r(s) = 0.12); office systolic BP, sitting (r(s) = 0.11), standing (r(s) = 0.10); estimated GFR (r(s) = 0.10); heart rate, sitting (r(s) = 0.10); haemoglobin (r(s) = -0.10); triacylglycerol (r(s) = 0.09); and uric acid (r(s) = -0.08; all p <or= 0.001). Significantly higher albumin excretion rates were found for the following categorical variables: higher waist circumference (more marked in men); presence of the metabolic syndrome; smoking (difference more marked in males); female sex; antihypertensive treatment; use of amlodipine; insulin treatment; family history of diabetes; and family history of cardiovascular disease (more marked in women). CONCLUSIONS/ INTERPRETATION: Although observational correlations do not prove causality, in normoalbuminuric type 2 diabeticpatients the albumin excretion rate is correlated with many factors that are potentially susceptible to intervention. TRIAL REGISTRATION: ClinicalTrials.gov ID no.: NCT00185159 FUNDING: This study was sponsored by Daichii-Sankyo.
Authors: Monique L Stone; Maria E Craig; Albert K Chan; Jenny W Lee; Charles F Verge; Kim C Donaghue Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: Hermann Haller; Gian C Viberti; Albert Mimran; Giuseppe Remuzzi; Antonius J Rabelink; Eberhard Ritz; Lars C Rump; Luis M Ruilope; Shigehiro Katayama; Sadayoshi Ito; Joseph L Izzo; Andrzej Januszewicz Journal: J Hypertens Date: 2006-02 Impact factor: 4.844
Authors: Jose Maria Pascual; Enrique Rodilla; Carmen Gonzalez; Santiago Pérez-Hoyos; Josep Redon Journal: Hypertension Date: 2005-05-16 Impact factor: 10.190
Authors: N R Robles; F J Felix; D Fernandez-Berges; J Perez-Castán; M J Zaro; L Lozano; P Alvarez-Palacios; A Garcia-Trigo; V Tejero; Y Morcillo; A B Hidalgo Journal: Int Urol Nephrol Date: 2013-01-26 Impact factor: 2.370
Authors: Niina Sandholm; Carol Forsblom; Ville-Petteri Mäkinen; Amy Jayne McKnight; Anne-May Osterholm; Bing He; Valma Harjutsalo; Raija Lithovius; Daniel Gordin; Maija Parkkonen; Markku Saraheimo; Lena M Thorn; Nina Tolonen; Johan Wadén; Jaakko Tuomilehto; Maria Lajer; Emma Ahlqvist; Anna Möllsten; M Loredana Marcovecchio; Jason Cooper; David Dunger; Andrew D Paterson; Gianpaolo Zerbini; Leif Groop; Lise Tarnow; Alexander P Maxwell; Karl Tryggvason; Per-Henrik Groop Journal: Diabetologia Date: 2014-03-05 Impact factor: 10.122
Authors: Lorenzo Villa-Zapata; Terri Warholak; Marion Slack; Daniel Malone; Anita Murcko; George Runger; Michael Levengood Journal: Int Urol Nephrol Date: 2015-12-11 Impact factor: 2.370
Authors: Amanda H Anderson; Dawei Xie; Xue Wang; Robin L Baudier; Paula Orlandi; Lawrence J Appel; Laura M Dember; Jiang He; John W Kusek; James P Lash; Sankar D Navaneethan; Akinlolu Ojo; Mahboob Rahman; Jason Roy; Julia J Scialla; James H Sondheimer; Susan P Steigerwalt; F Perry Wilson; Myles Wolf; Harold I Feldman Journal: Am J Kidney Dis Date: 2020-08-28 Impact factor: 8.860
Authors: Graham S Hillis; Jun Hata; Mark Woodward; Vlado Perkovic; Hisatomi Arima; Clara K Chow; Sophia Zoungas; Anushka Patel; Neil R Poulter; Giuseppe Mancia; Bryan Williams; John Chalmers Journal: J Am Heart Assoc Date: 2012-10-25 Impact factor: 5.501